Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Description and Characterization of a Novel Human Mast Cell Line for Scientific Study.

Kirshenbaum AS, Yin Y, Sundstrom JB, Bandara G, Metcalfe DD.

Int J Mol Sci. 2019 Nov 6;20(22). pii: E5520. doi: 10.3390/ijms20225520.

2.

Maculopapular Cutaneous Mastocytosis in a Diverse Population.

Kirshenbaum AS, Abuhay H, Bolan H, Metcalfe DD, Carter MC.

J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2845-2847. doi: 10.1016/j.jaip.2019.04.003. Epub 2019 May 2. No abstract available.

PMID:
31056447
3.

Immunophenotypic and Ultrastructural Analysis of Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection to Pulmonary Fibrosis.

Kirshenbaum AS, Cruse G, Desai A, Bandara G, Leerkes M, Lee CC, Fischer ER, O'Brien KJ, Gochuico BR, Stone K, Gahl WA, Metcalfe DD.

PLoS One. 2016 Jul 26;11(7):e0159177. doi: 10.1371/journal.pone.0159177. eCollection 2016.

4.

IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3.

Desai A, Jung MY, Olivera A, Gilfillan AM, Prussin C, Kirshenbaum AS, Beaven MA, Metcalfe DD.

J Allergy Clin Immunol. 2016 Jun;137(6):1863-1871.e6. doi: 10.1016/j.jaci.2015.09.059. Epub 2016 Jan 7.

5.

Helicobacter pylori: A significant and treatable cause of chronic urticaria and angioedema.

Rasooly MM, Moye NA, Kirshenbaum AS.

Nurse Pract. 2015 Oct 16;40(10):1-6. doi: 10.1097/01.NPR.0000471366.32982.f2.

PMID:
26383021
6.

Growth of human mast cells from bone marrow and peripheral blood-derived CD34(+) pluripotent hematopoietic cells.

Bandara G, Metcalfe DD, Kirshenbaum AS.

Methods Mol Biol. 2015;1220:155-62. doi: 10.1007/978-1-4939-1568-2_10.

7.

A ten-year retrospective analysis of the distribution, use and phenotypic characteristics of the LAD2 human mast cell line.

Kirshenbaum AS, Petrik A, Walsh R, Kirby TL, Vepa S, Wangsa D, Ried T, Metcalfe DD.

Int Arch Allergy Immunol. 2014;164(4):265-70. doi: 10.1159/000365729. Epub 2014 Sep 3.

8.

Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Chan EC, Bai Y, Kirshenbaum AS, Fischer ER, Simakova O, Bandara G, Scott LM, Wisch LB, Cantave D, Carter MC, Lewis JC, Noel P, Maric I, Gilfillan AM, Metcalfe DD, Wilson TM.

J Allergy Clin Immunol. 2014 Jul;134(1):178-87. doi: 10.1016/j.jaci.2013.12.1090. Epub 2014 Feb 28.

9.

Glycomic analysis of human mast cells, eosinophils and basophils.

North SJ, von Gunten S, Antonopoulos A, Trollope A, MacGlashan DW Jr, Jang-Lee J, Dell A, Metcalfe DD, Kirshenbaum AS, Bochner BS, Haslam SM.

Glycobiology. 2012 Jan;22(1):12-22. doi: 10.1093/glycob/cwr089. Epub 2011 Jul 1.

10.

IgE-FcepsilonRI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells.

Sundstrom JB, Hair GA, Ansari AA, Secor WE, Gilfillan AM, Metcalfe DD, Kirshenbaum AS.

J Immunol. 2009 May 15;182(10):6401-9. doi: 10.4049/jimmunol.0801481.

11.

Effect of lipopolysaccharide (LPS) and peptidoglycan (PGN) on human mast cell numbers, cytokine production, and protease composition.

Kirshenbaum AS, Swindle E, Kulka M, Wu Y, Metcalfe DD.

BMC Immunol. 2008 Aug 7;9:45. doi: 10.1186/1471-2172-9-45.

12.

Human tissue mast cells are an inducible reservoir of persistent HIV infection.

Sundstrom JB, Ellis JE, Hair GA, Kirshenbaum AS, Metcalfe DD, Yi H, Cardona AC, Lindsay MK, Ansari AA.

Blood. 2007 Jun 15;109(12):5293-300. Epub 2007 Mar 9.

13.
15.

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.

Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD.

Exp Hematol. 2003 Aug;31(8):686-92.

PMID:
12901973
16.

Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI.

Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD.

Leuk Res. 2003 Aug;27(8):677-82. Erratum in: Leuk Res. 2003 Dec;27(12):1171.

PMID:
12801524
17.

An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells.

Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD.

Am J Clin Pathol. 2002 Aug;118(2):242-7.

PMID:
12162685
18.

Induction of telomerase activity during development of human mast cells from peripheral blood CD34+ cells: comparisons with tumor mast-cell lines.

Chaves-Dias C, Hundley TR, Gilfillan AM, Kirshenbaum AS, Cunha-Melo JR, Metcalfe DD, Beaven MA.

J Immunol. 2001 Jun 1;166(11):6647-56.

19.
20.
21.

Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13).

Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD.

Blood. 1999 Oct 1;94(7):2333-42.

PMID:
10498605
22.

Inhibition of human mast cell growth and differentiation by interferon gamma-1b.

Kirshenbaum AS, Worobec AS, Davis TA, Goff JP, Semere T, Metcalfe DD.

Exp Hematol. 1998 Mar;26(3):245-51.

PMID:
9502621
23.

Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact.

Bhattacharyya SP, Drucker I, Reshef T, Kirshenbaum AS, Metcalfe DD, Mekori YA.

J Leukoc Biol. 1998 Mar;63(3):337-41.

PMID:
9500521
24.

Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16.

Rumsaeng V, Cruikshank WW, Foster B, Prussin C, Kirshenbaum AS, Davis TA, Kornfeld H, Center DM, Metcalfe DD.

J Immunol. 1997 Sep 15;159(6):2904-10.

PMID:
9300714
25.

Treatment of three patients with systemic mastocytosis with interferon alpha-2b.

Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD.

Leuk Lymphoma. 1996 Aug;22(5-6):501-8.

PMID:
8882964
26.
27.

Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells.

Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD.

J Immunol. 1992 Feb 1;148(3):772-7.

PMID:
1370517
28.

Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells.

Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD.

J Immunol. 1991 Mar 1;146(5):1410-5.

PMID:
1704394
29.

Early development of mast cells.

Rottem M, Kirshenbaum AS, Metcalfe DD.

Int Arch Allergy Appl Immunol. 1991;94(1-4):104-9.

PMID:
1718881
30.

Sequential appearance of basophils and mast cells from human bone marrow in long-term suspension culture.

Bressler RB, Friedman MM, Kirshenbaum AS, Irani AM, Schwartz LB, Metcalfe DD.

Int Arch Allergy Appl Immunol. 1990;91(4):403-10.

PMID:
1698724
32.

Human macrophages cultured on agar but not agarose resemble mast cells.

Kirshenbaum AS, Goff JP, Metcalfe DD.

Immunology. 1989 Sep;68(1):120-5.

33.

IL-3-dependent growth of basophil-like cells and mastlike cells from human bone marrow.

Kirshenbaum AS, Goff JP, Dreskin SC, Irani AM, Schwartz LB, Metcalfe DD.

J Immunol. 1989 Apr 1;142(7):2424-9.

PMID:
2647850
34.

Mastocytosis in infants and children: recognition of patterns of skin disease.

Kirshenbaum AS, Kettelhut BV, Metcalfe DD, Garriga MM.

Allergy Proc. 1989 Jan-Feb;10(1):17-21.

PMID:
2925086
35.

Characterization of basophil-like cells derived from nonhuman primate bone marrow.

Kirshenbaum AS, Bressler RB, Friedman MM, Metcalfe DD.

Int Arch Allergy Appl Immunol. 1988;87(1):1-8.

PMID:
2459067
36.

A formula for calculating the dosages of drugs in emergencies.

Kirshenbaum AS.

JAMA. 1987 Feb 6;257(5):629. No abstract available.

PMID:
3795444
37.

Theophylline dosage.

Kirshenbaum AS, Frick OL.

Pediatrics. 1982 Sep;70(3):498-9. No abstract available.

PMID:
7110827
38.

Congenital intrathoracic kidney: a 5-year radionuclide follow-up.

Rao BR, Kirshenbaum AS, Puri HC, Winebright JW.

Eur J Nucl Med. 1981 Apr;6(4):177-8.

PMID:
7215383

Supplemental Content

Loading ...
Support Center